血小板生成素受体激动剂在遗传性血小板减少症中的应用
本文综述血小板生成素受体激动剂(TPO-RAs)治疗遗传性血小板减少症(HTPs)的现有临床数据,指出初步临床证据显示TPO-RAs耐受性良好并带来临床获益,可考虑用于部分类型HTPs,但因缺乏长期安全性数据及长期骨髓刺激的潜在风险,建议谨慎并密切监测。
要点
- TPO-RAs在部分类型HTPs中耐受性良好并带来临床获益,可考虑用于临床实践。
- 因缺乏长期安全性数据及长期骨髓刺激的潜在风险,建议谨慎并密切监测。
- 作者认为TPO-RAs将在HTPs治疗中发挥重要作用,尤其是肌球蛋白重链9相关疾病、Wiskott-Aldrich综合征、X连锁血小板减少症及THPO突变所致血小板减少症。
核心结论
- 初步临床证据提示,已用于某些获得性血小板减少症治疗的TPO-RAs在部分类型HTPs患者中耐受性良好并提供临床获益。
- 这些药物或可考虑用于临床实践中HTPs的治疗。
- 由于缺乏长期安全性数据及长期骨髓刺激在某些HTPs中的潜在风险,建议谨慎并密切监测。
- 作者认为TPO-RAs将在HTPs治疗中发挥重要作用,尤其是肌球蛋白重链9相关疾病、Wiskott-Aldrich综合征、X连锁血小板减少症及THPO突变所致血小板减少症。
研究设计与样本
- 本文为综述,汇总TPO-RAs治疗HTPs的现有临床数据并讨论其在这些疾病患者中的应用。
主要发现
- 大多数HTPs缺乏有效治疗,仅在出血时及准备有出血风险的操作时进行血小板输注。
- 初步临床证据提示,TPO-RAs在部分类型HTPs患者中耐受性良好并提供临床获益。
临床怎么用
- 作者认为这些药物或可考虑用于临床实践中HTPs的治疗。
- 作者建议谨慎并密切监测,原因在于缺乏长期安全性数据及长期骨髓刺激在某些HTPs中的潜在风险。
局限性
- 缺乏长期安全性数据。
- 长期骨髓刺激在某些HTPs中存在潜在风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hereditary thrombocytopenias (HTPs) constitute a heterogeneous group of diseases characterized by a reduction in platelet count and a potential bleeding risk. As a result of advances in diagnostic methods, HTPs are increasingly being identified, and appear to be less rare than previously thought. Most HTPs do not have effective treatments, except for platelet transfusion when bleeding occurs and in preparation for procedures associated with a risk of bleeding. Preliminary clinical evidence suggests that thrombopoietin receptor agonists (TPO-RAs) with an established use in the treatment of certain acquired thrombocytopenias are well tolerated and provide clinical benefits in patients with some forms of HTP. These drugs may therefore be considered for the treatment of HTPs in clinical practice. However, caution and close monitoring are recommended, owing to the absence of long-term safety data and the potential risks posed by prolonged bone marrow stimulation in certain HTPs. In this review, we summarize the available clinical data on TPO-RAs in the treatment of HTPs, and discuss their use in patients with these disorders. We believe that TPO-RAs will play a major role in the treatment of HTPs, particularly myosin heavy chain 9-related disease, Wiskott-Aldrich syndrome, X-linked thrombocytopenia, and thrombocytopenia caused by THPO mutations.
引用
- Rodeghiero F, Pecci A, Balduini CL, et al. Thrombopoietin receptor agonists in hereditary thrombocytopenias. J Thromb Haemost. 2018. PMID: 29956472. doi:10.1111/jth.14217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。